516481-95-1

Upstream product

• 6294-93-5 4-chloro-3-trifluoromethylphenol 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 516481-94-0 2-[4-(4-Chloro-3-trifluoromethyl-phenoxy)-phenyl]-1H-benzoimidazole-5-sulfonic Acid Amide 
• 1369254-70-5 1-chloro-4-(4-(difluoromethyl)phenoxy)-2-(trifluoromethyl)benzene 
• 1369254-71-6 1-chloro-4-(4-(chlorodifluoromethyl)phenoxy)-2-(trifluoromethyl)benzene 
• 1380429-33-3 (E)-1-chloro-4-(4-(2-nitrovinyl)phenoxy)-2-(trifluoromethyl)benzene 
• 1369254-73-8 4-chloro-3-(trifluoromethyl)phenyl 4-ethenylphenyl ether 
• 1380429-32-2 1-(4-(4-chloro-3-(trifluoromethyl)phenoxy)phenyl)-N-methylmethylamine 
• 1380429-29-7 (2E)-3-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)-2-propenenitrile 
• 1369255-78-6 1-chloro-4-(4-(chloromethyl)phenoxy)-2-(trifluoromethyl)benzene 
• 1369254-76-1 2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethanol 
• 1380426-84-5 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-5-{[2-(methyloxy)-5-pyrimidinyl]methyl}-4(1H)-pyrimidinone 
• 1380426-85-6 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone 
• 1380428-23-8 2-(4-(4-chloro-3-(trifluoromethyl)phenoxy)phenethoxy)-5-(2,2,2-trifluoroethyl)pyrimidin-4(1H)-one 
• 1380428-24-9 2-(4-(4-chloro-3-(trifluoromethyl)phenoxy)phenethoxy)-1-methyl-5-(2,2,2-trifluoroethyl)pyrimidin-4(1H)-one 
• 1380426-86-7 2-{[2-(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)ethyl]amino}-5-(5-pyrimidinylmethyl)-4(1H)-pyrimidinone 

Relevant academic research and scientific papers

PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF

The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, Rs

Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors

Inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) has been suggested to be a promising therapeutic strategy for several inflammation-associated diseases, including atherosclerosis, Alzheimer's disease, and diabetic macu

2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS

Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

BICYCLIC PYRIMIDONE COMPOUNDS

The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

BICYCLIC PYRIMIDONE COMPOUNDS

The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS

Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer?s disease

TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).